Aelis Farma SA
PAR:AELIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aelis Farma SA
Cash from Operating Activities
Aelis Farma SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aelis Farma SA
PAR:AELIS
|
Cash from Operating Activities
-€11.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Operating Activities
-€52.9m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Operating Activities
-€26.2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-6%
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Operating Activities
-€104.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash from Operating Activities
-$120.5m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-16%
|
|
|
Abivax SA
PAR:ABVX
|
Cash from Operating Activities
-€97.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Aelis Farma SA
Glance View
Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
See Also
What is Aelis Farma SA's Cash from Operating Activities?
Cash from Operating Activities
-11.8m
EUR
Based on the financial report for Dec 31, 2024, Aelis Farma SA's Cash from Operating Activities amounts to -11.8m EUR.
What is Aelis Farma SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-33%
Over the last year, the Cash from Operating Activities growth was 9%.
